This segment focuses on the research, development, and commercialization of novel medicines for neurological and psychiatric disorders. Sage Therapeutics is actively involved in clinical trials for zuranolone, targeting major depressive disorder (MDD), postpartum depression (PPD), treatment-resistant depression, generalized anxiety disorder (GAD), and bipolar depression. The company utilizes advanced methodologies in drug discovery, including neuroactive steroid research, to develop therapies that address significant unmet needs in mental health. Patient impact is addressed by providing innovative treatment options for individuals suffering from debilitating conditions. Sage's market positioning is strengthened by its focus on brain health and its collaborations with companies like Biogen and Shionogi. Future opportunities include expanding the use of zuranolone and advancing other pipeline candidates. Regulatory aspects involve obtaining FDA approval for new drug applications. Partnerships with Biogen and Shionogi support the commercialization and development of key products.

This segment is dedicated to the development and commercialization of treatments specifically for postpartum depression (PPD). The lead product, ZULRESSO (brexanolone), is an intravenous formulation approved for PPD. Research and development efforts are focused on improving the efficacy and accessibility of PPD treatments. The company utilizes advanced pharmaceutical formulations and clinical trial methodologies to evaluate the safety and effectiveness of its products. The primary therapeutic area is women's health, with a focus on improving the lives of mothers experiencing PPD. Patient impact is significant, as ZULRESSO provides a much-needed treatment option for a condition that affects many women. Sage's market position is strong due to its first-mover advantage in the PPD treatment space. Future opportunities include expanding the use of ZULRESSO and developing oral treatments for PPD. Regulatory aspects involve obtaining and maintaining FDA approval for ZULRESSO and other PPD treatments. The company is also exploring partnerships to expand the reach of its products.

This segment focuses on the development of treatments for essential tremors and other neurological conditions. Sage is conducting Phase II clinical trials for SAGE-324, a compound being investigated for essential tremors, and has completed Phase I trials for epilepsy and Parkinson's disease. The company employs advanced drug discovery techniques and clinical trial methodologies to evaluate the safety and efficacy of its product candidates. The therapeutic areas include neurology, with a focus on addressing unmet needs in movement disorders and other neurological conditions. Patient impact is addressed by providing potential treatment options for individuals suffering from debilitating neurological conditions. Sage's market positioning is based on its innovative approach to treating neurological disorders. Future opportunities include expanding the clinical development of SAGE-324 and exploring other potential indications. Regulatory aspects involve obtaining FDA approval for new drug applications. The company is actively seeking partnerships to advance its research and development efforts in this area.